CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 79 enrolled
Drug / intervention
Placebo SC +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02388347
NCT02388347Phase 1Completed
CompareCT.gov

A Phase 1a, Randomised, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI7836 in Healthy Adults

MedImmune LLC·interventional·Posted Mar 17, 2015·Updated May 16, 2017

In Brief

A Phase 1 clinical trial evaluating Placebo SC, MEDI7836 Dose 1, and 3 other interventions for Healthy Adults. Completed, enrolled 79 participants across 1 site.

Detailed Summary

To assess the safety of a single ascending dose of MEDI7836 in healthy adult male subjects and healthy adult female subjects of non-childbearing potential.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adults
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 17, 2015
Enrollment StartMar 1, 2015
Primary CompletionJan 1, 2016
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.3 years ago

Interventions

Placebo SCdrug

Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.

MEDI7836 Dose 1biological

Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.

MEDI7836 Dose 2biological

Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.

MEDI7836 Dose 3biological

Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.

MEDI7836 Dose 4biological

Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.